BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22436003)

  • 1. Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
    Haddad M; Beray-Berthat V; Coqueran B; Plotkine M; Marchand-Leroux C; Margaill I
    Fundam Clin Pharmacol; 2013 Aug; 27(4):393-401. PubMed ID: 22436003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
    Teng F; Beray-Berthat V; Coqueran B; Lesbats C; Kuntz M; Palmier B; Garraud M; Bedfert C; Slane N; Bérézowski V; Szeremeta F; Hachani J; Scherman D; Plotkine M; Doan BT; Marchand-Leroux C; Margaill I
    Exp Neurol; 2013 Oct; 248():416-28. PubMed ID: 23876515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice.
    Haddad M; Beray-Berthat V; Coqueran B; Palmier B; Szabo C; Plotkine M; Margaill I
    Eur J Pharmacol; 2008 Jun; 588(1):52-7. PubMed ID: 18468597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
    El Amki M; Lerouet D; Garraud M; Teng F; Beray-Berthat V; Coqueran B; Barsacq B; Abbou C; Palmier B; Marchand-Leroux C; Margaill I
    Mol Neurobiol; 2018 Dec; 55(12):9156-9168. PubMed ID: 29651748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
    Abdelkarim GE; Gertz K; Harms C; Katchanov J; Dirnagl U; Szabó C; Endres M
    Int J Mol Med; 2001 Mar; 7(3):255-60. PubMed ID: 11179503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice.
    Haddad M; Rhinn H; Bloquel C; Coqueran B; Szabó C; Plotkine M; Scherman D; Margaill I
    Br J Pharmacol; 2006 Sep; 149(1):23-30. PubMed ID: 16865091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia.
    Greco R; Tassorelli C; Mangione AS; Levandis G; Certo M; Nappi G; Bagetta G; Blandini F; Amantea D
    Eur J Pharmacol; 2014 Dec; 744():91-7. PubMed ID: 25446913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
    Crome O; Doeppner TR; Schwarting S; Müller B; Bähr M; Weise J
    J Neurosci Res; 2007 Jun; 85(8):1734-43. PubMed ID: 17455321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
    El Amki M; Lerouet D; Coqueran B; Curis E; Orset C; Vivien D; Plotkine M; Marchand-Leroux C; Margaill I
    Exp Neurol; 2012 Dec; 238(2):138-44. PubMed ID: 22921458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice.
    Chen TY; Lee MY; Chen HY; Kuo YL; Lin SC; Wu TS; Lee EJ
    J Pineal Res; 2006 Apr; 40(3):242-50. PubMed ID: 16499561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats.
    Lenzsér G; Kis B; Snipes JA; Gáspár T; Sándor P; Komjáti K; Szabó C; Busija DW
    J Cereb Blood Flow Metab; 2007 Jul; 27(7):1318-26. PubMed ID: 17213862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model.
    Maeda M; Furuichi Y; Noto T; Matsuoka N; Mutoh S; Yoneda Y
    Brain Res; 2009 Feb; 1254():99-108. PubMed ID: 19101526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.
    Scott GS; Kean RB; Mikheeva T; Fabis MJ; Mabley JG; Szabó C; Hooper DC
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1053-61. PubMed ID: 15159442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant tissue plasminogen activator enhances microparticle release from mouse brain-derived endothelial cells through plasmin.
    Garraud M; Khacef K; Vion AC; Leconte C; Yin M; Renard JM; Marchand-Leroux C; Boulanger CM; Margaill I; Beray-Berthat V
    J Neurol Sci; 2016 Nov; 370():187-195. PubMed ID: 27772757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
    Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
    J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local administration of the Poly ADP-Ribose Polymerase (PARP) inhibitor, PJ34 during hindlimb ischemia modulates skeletal muscle reperfusion injury.
    Conrad MF; Albadawi H; Stone DH; Crawford RS; Entabi F; Watkins MT
    J Surg Res; 2006 Oct; 135(2):233-7. PubMed ID: 16872633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMTP-7, a new thrombolytic agent, decreases hemorrhagic transformation after transient middle cerebral artery occlusion under warfarin anticoagulation in mice.
    Ito A; Niizuma K; Shimizu H; Fujimura M; Hasumi K; Tominaga T
    Brain Res; 2014 Aug; 1578():38-48. PubMed ID: 25016287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PJ34, a poly-ADP-ribose polymerase inhibitor, modulates visceral mitochondrial activity and CD14 expression following thoracic aortic ischemia-reperfusion.
    Stone DH; Albadawi H; Conrad MF; Entabi F; Stoner MC; Casey PJ; Cambria RP; Watkins MT
    Am J Surg; 2009 Aug; 198(2):250-5. PubMed ID: 19268911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.